P
TXG icon

Pitcairn’s 10x Genomics TXG Stock Holding History

Pitcairn’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,648
Closed -$212K – 746
2024
Q1 		$212K Sell
5,648
-1,259
-18% -$55.3K 0.01% 676
2023
Q4 		$387K Sell
6,907
-656
-9% -$28.5K 0.03% 474
2023
Q3 		$312K Sell
7,563
-1,318
-15% -$68.6K 0.03% 492
2023
Q2 		$496K Buy
8,881
+1,342
+18% +$72.6K 0.04% 359
2023
Q1 		$421K Buy
7,539
+1,898
+34% +$88.6K 0.04% 389
2022
Q4 		$206K Buy
+5,641
New +$184K 0.02% 561
2022
Q3 		– Sell
-5,507
Closed -$249K – 600
2022
Q2 		$249K Buy
5,507
+1,653
+43% +$85.8K 0.03% 495
2022
Q1 		$293K Buy
3,854
+2,480
+180% +$217K 0.03% 501
2021
Q4 		$205K Buy
+1,374
New +$210K 0.01% 613

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Pitcairn's TXG Position: Q2 2024 in Review

Pitcairn sold out of 10x Genomics (TXG) in Q2 2024, closing a stake of 5,648 shares — an estimated $212K sold.

Pitcairn first reported a position in TXG in Q4 2021 and held it in 9 quarters. The position peaked at $496K in Q2 2023. 261 funds tracked by Wall St. Rank hold TXG as of Q2 2024.

  • Pitcairn reported no remaining 10x Genomics position as of Q2 2024 after selling out during the quarter.
  • Pitcairn sold 5,648 10x Genomics shares in Q2 2024, an estimated $212K.
  • Pitcairn first reported a position in 10x Genomics in Q4 2021 and held it in 9 quarters.
  • Pitcairn's 10x Genomics position peaked at $496K in Q2 2023.
  • 261 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2024.

Based on Pitcairn's 13F filing for Q2 2024, filed 13 Aug 2024.